09/03/2021 (Agence Europe) – The Covid-19 vaccine marketed by Johnson & Johnson, which has yet to be authorised before being marketed in Europe, could be subject to delivery delays in the second quarter. This was revealed on Tuesday 9 March by the Reuters press agency after communication with a European official. By their account, J&J would face supply problems that would “put pressure” on its ability to meet its target of delivering 55 million doses by the end of June, saying the target could be met, but that there was no certainty at this stage. (SPj)